DNPUF (Sumitomo Pharma Co) Shiller PE Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNPUF Sumitomo Pharma Co Ltd DNPUF
57 GF Score
Price $9.79
GF Value $5.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sumitomo Pharma Co  (OTCPK:DNPUF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sumitomo Pharma Co Shiller PE Ratio Related Terms


Sumitomo Pharma Co Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Shiller PE Ratio Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.12 9.13 21.43 41.36 57.79

Sumitomo Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.46 46.32 57.67 60.90 38.25

DNPUF vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Shiller PE Ratio falls into.


DNPUF
57GF Score
Sumitomo Pharma Co Ltd DNPUF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sumitomo Pharma Co's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.2448/113.6000*113.6000
=0.245

Current CPI (Jun. 2026) = 113.6000.

Sumitomo Pharma Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 0.195 98.100 0.226
201609 0.063 98.000 0.073
201612 0.429 98.400 0.495
201703 -0.013 98.100 -0.015
201706 0.558 98.500 0.643
201709 0.464 98.800 0.534
201712 -0.032 99.400 -0.037
201806 0.352 99.200 0.403
201809 0.285 99.900 0.324
201812 0.270 99.700 0.308
201903 0.198 99.700 0.225
201906 0.154 99.800 0.175
201909 0.554 100.100 0.629
201912 0.316 100.500 0.357
202003 -0.075 100.300 -0.084
202006 0.427 99.900 0.486
202009 0.451 99.900 0.513
202012 0.794 99.300 0.908
202103 -0.333 99.900 -0.379
202106 0.111 99.500 0.126
202109 0.724 100.100 0.821
202112 0.219 100.100 0.249
202203 0.218 101.100 0.245
202206 0.604 101.800 0.674
202209 -0.699 103.100 -0.770
202212 -0.200 104.100 -0.218
202303 -1.065 104.400 -1.159
202306 -0.712 105.200 -0.769
202309 -0.503 106.200 -0.538
202312 -0.850 106.800 -0.904
202403 -3.344 107.200 -3.544
202406 0.258 108.200 0.270
202409 -0.812 108.900 -0.847
202412 0.883 110.700 0.906
202503 0.040 111.100 0.041
202506 0.195 111.700 0.198
202509 1.497 112.000 1.518
202512 0.144 113.000 0.145
202603 -0.013 112.700 -0.013
202606 0.245 113.600 0.245

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of $9.79 is trading 69.4% above its estimated GF Value™ of $5.78. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for DNPUF:

  • Shiller PE Ratio:
  • GF Value™: $5.78 vs. price of $9.79 (69.4% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
57GF Score

Get the complete analysis for DNPUF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.79
Price
$5.78
GF Value